Discriminatory Immunohistochemical Staining of Urothelial Carcinoma in Situ and Non-neoplastic Urothelium
Authors:
- 1 August 2001
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 25 (8) , 1074-1078
Abstract
Distinction of urothelial carcinoma in situ (CIS) from reactive atypia on the basis of morphology alone may be difficult in some cases. Because this distinction is therapeutically and prognostically critical, we attempted to determine if an immunohistochemical panel would help in this differential diagnosis. The immunoprofile of 21 cases of CIS and 25 non-neoplastic urothelia (15 urothelial biopsies with reactive atypia from patients without a history of bladder cancer and 10 normal ureter sections from nephrectomies performed for renal cell carcinoma) was determined using antibodies against cytokeratin 20 (CK20), p53, and CD44 (standard isoform). In the normal urothelium CK20 showed patchy cytoplasmic immunoreactivity in only the superficial umbrella cell layer and CD44 stained only the basal cells. Nuclear immunoreactivity to p53 varied from negative to weak and patchy. Reactive urothelium also showed CK20 immunoreactivity in only the umbrella cell layer in all 15 cases, and p53 nuclear staining was predominantly negative with occasional weak positivity in the basal and parabasal intermediate cells. CD44 was overexpressed in the entire reactive urothelium in 9 cases (60%) or focally positive in intermediate cells in 6 cases (40%). In contrast, CIS showed intense CK20 and p53 positivity (81% and 57%, respectively) in the majority (>50%) of malignant cells. CD44 staining revealed residual basal cells with membranous reactivity in 44% of the cases of CIS; however, the neoplastic cells were immunonegative in all cases. At least one positive immunomarker (CK20 or p53) was abnormally expressed in all cases of CIS. Abnormal expression of CK20 (increased), p53 (increased), and CD44 (decreased) in urothelial CIS, and increased expression of CD44 in reactive atypia allows more confident distinction of urothelial CIS from non-neoplastic urothelial atypias. From a differential diagnosis perspective, use of a panel of all three antibodies with morphologic correlation would be essential.Keywords
This publication has 26 references indexed in Scilit:
- Relationship of Cytokeratin 20 and CD44 Protein Expression with WHO/ISUP Grade in pTa and pT1 Papillary Urothelial NeoplasiaLaboratory Investigation, 2000
- Cytokeratin 7 and Cytokeratin 20 Expression in Epithelial Neoplasms: A Survey of 435 CasesLaboratory Investigation, 2000
- Focal Loss of CD44 Variant Protein Expression is Related to Recurrence in Superficial Bladder CarcinomaThe American Journal of Pathology, 1999
- Cytokeratin 20 as an objective marker of urothelial dysplasiaBritish Journal of Urology, 1996
- Unusual retention of introns in CD44 gene transcripts in bladder cancer provides new diagnostic and clinical oncological opportunitiesThe Journal of Pathology, 1995
- Cytokeratin 20 expression by non‐invasive transitional cell carcinomas: potential for distinguishing recurrent from non‐recurrent diseaseHistopathology, 1995
- Accumulation of p53 Protein as an Indicator for p53 Gene Mutation in Breast CancerDiagnostic Molecular Pathology, 1993
- Natural history of early bladder cancerJournal of Cellular Biochemistry, 1992
- The p53 tumour suppressor geneNature, 1991
- Increased expression of mutant forms of p53 oncogene in primary lung cancerThe Lancet, 1990